glucose, (beta-d)-isomer has been researched along with Diabetic Angiopathies in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 48 (90.57) | 24.3611 |
| 2020's | 5 (9.43) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, R; Liu, LY; Lu, L; Ni, SH; Wang, M; Wang, MQ; Wang, YJ; Wei, LB; Wu, XH; You, HY | 1 |
| Cauchon, M; Dussault, C; Huard, G; Lanthier, L; Plourde, MÉ | 1 |
| Chan, YY; Chang, KC; Hung, MJ; Kao Yang, YH; Lai, EC; Lin, YH; Shao, SC | 1 |
| Inoue, T; Kusakabe, T; Odori, S; Satoh-Asahara, N; Shimatsu, A; Tanaka, M; Yamakage, H | 1 |
| Choy, AMJ; Donnan, PT; Fathi, A; Gandy, S; George, J; Houston, JG; Khan, F; Lang, CC; Mohan, M; Mordi, IR; Pearson, ER; Singh, JSS; Struthers, AD; Vickneson, K | 1 |
| Fonseca, VA; Shao, H; Shi, L | 1 |
| Krzesinski, JM; Paquot, N; Piérard, L; Scheen, AJ | 1 |
| Chilton, R; Hehnke, U; Johansen, OE; Tikkanen, I; Woerle, HJ | 1 |
| Ahn, YB; Cha, SA; Ko, SH; Lim, TS; Park, YM; Song, KH; Yoo, KD; Yun, JS | 1 |
| Palau, V; Riera, M; Soler, MJ | 1 |
| Wanner, C | 2 |
| Chilton, R; Pham, SV | 1 |
| Lehrke, M; Marx, N | 2 |
| Staels, B | 2 |
| Perreault, L | 2 |
| Chilton, RJ; Pham, SV | 1 |
| Birkeland, KI; Bodegard, J; Carstensen, B; Eriksson, JW; Fenici, P; Gulseth, HL; Jørgensen, ME; Nathanson, D; Norhammar, A; Nyström, T; Persson, F; Thuresson, M | 1 |
| Coleman, CI; Nair, S; Nguyen, E; Weeda, ER | 1 |
| Bluhmki, E; Ferrannini, E; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; Ohneberg, K; Schmoor, C; Schumacher, M; Wanner, C; Zinman, B | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD | 1 |
| Covino, J; Hoffman, J | 1 |
| Battson, ML; Ecton, KE; Gentile, CL; Hou, S; Jarrell, DK; Lee, DM; Weir, TL | 1 |
| Bekki, M; Fukumoto, Y; Honda, A; Igata, S; Kumashiro, Y; Matsui, T; Nakamura, T; Sugiyama, Y; Sun, J; Tahara, A; Tahara, N; Yamagishi, SI | 1 |
| Ren, DY; Zhang, Y | 1 |
| Adimadhyam, S; Calip, GS; Layden, BT; Lee, TA; Schumock, GT; Smith Marsh, DE | 1 |
| Aroor, AR; Carpenter, AJ; Chandrasekar, B; Das, NA; DeMarco, VG; Duta, C; Habibi, J; Hayden, MR; Jia, G; Manrique-Acevedo, CM; Martinez-Lemus, L; Mayoux, E; Nistala, R; Padilla, J; Ramirez-Perez, FI | 1 |
| Abdurrachim, D; Chan, WX; Lalic, J; Lam, CSP; Lee, PTH; Teo, XQ; Woo, CC | 1 |
| Cain, VA; Hallow, MK; Heerspink, HJL; Inzucchi, SE; Rossing, P; Sartipy, P; Sjöström, CD; Stefansson, BV | 1 |
| Bodegård, J; Eriksson, JW; Nathanson, D; Norhammar, A; Nyström, T; Thuresson, M | 1 |
| Arena, S; Avogaro, A; Berchialla, P; Bottigliengo, D; Buzzetti, R; D'Angelo, P; Fadini, GP; Franzetti, I; Sciannameo, V; Vinci, C | 1 |
| George, JT; Kandaswamy, P; Kansal, A; Pfarr, E; Proskorovsky, I; Reifsnider, OS; Ruffolo, A; Zheng, Y | 1 |
| Liu, Y; Wang, X; Wang, Y; Xia, M; Zhang, Y | 1 |
| Bae, JS; Ku, SK; Lee, D; Lee, T; Lee, W | 1 |
| Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J | 1 |
| Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS | 1 |
| Broedl, UC; Green, A; Narko, K; Salsali, A; Tikkanen, I; Woerle, HJ; Zeller, C | 1 |
| Agdauletova, S; Bottari, SP; Daiber, A; Gottschlich, A; Hausding, M; Jansen, T; Kröller-Schön, S; Mader, M; Mayoux, E; Mikhed, Y; Münzel, T; Oelze, M; Schulz, E; Stamm, P; Steven, S; Welschof, P; Zinßius, E | 1 |
| Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Leiter, LA; Parikh, SJ; Sugg, J | 1 |
| Broedl, UC; Cannon, CP; Chilton, R; Crowe, S; Johansen, OE; Tikkanen, I; Woerle, HJ | 1 |
| Peters, MN; Pollock, JS; Rajagopalan, S | 1 |
| Overbeck, P | 1 |
| Chilton, R; Johansen, OE; Tikkanen, I | 1 |
| Abdul-Ghani, M; Chilton, R; Clarke, G; DeFronzo, RA; Norton, L; Ryder, RE | 1 |
| Ferrannini, E; Mark, M; Mayoux, E | 1 |
| Javor, E; Lucijanić, T; Rahelić, D; Skelin, M | 1 |
| Eguchi, K; Higashi, Y; Inoue, T; Ishizu, T; Kadokami, T; Kario, K; Kitakaze, M; Kodera, S; Maemura, K; Matsuhisa, M; Murohara, T; Nanasato, M; Nishio, Y; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Shimabukuro, M; Suzuki, M; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H | 1 |
| Fioretto, P; Inzucchi, SE; Vettor, R | 1 |
| Alzaid, A | 1 |
11 review(s) available for glucose, (beta-d)-isomer and Diabetic Angiopathies
| Article | Year |
|---|---|
[Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Treatment Outcome | 2016 |
Diabetes Mellitus and Heart Failure.
Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Prevalence; Prognosis | 2017 |
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Hemodynamics; Hormones; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Hemodynamics; Hormones; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Diabetes Mellitus and Heart Failure.
Topics: Benzhydryl Compounds; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Prevalence; Prognosis | 2017 |
EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
EMPA-REG OUTCOME: The Cardiologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2017 |
Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diuretics; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Resistance; Weight Loss | 2016 |
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Incidence; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
13 trial(s) available for glucose, (beta-d)-isomer and Diabetic Angiopathies
| Article | Year |
|---|---|
Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Uric Acid; Young Adult | 2020 |
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
Topics: Aged; Benzhydryl Compounds; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Placebos; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Remodeling | 2020 |
Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Rate; Humans; Hypertension; Male; Middle Aged; Treatment Outcome | 2017 |
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Risk Factors; Treatment Outcome | 2018 |
DECLARE-TIMI 58: Participants' baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Obesity; Prevalence; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardio Ankle Vascular Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Substitution; Female; Glucosides; Glycation End Products, Advanced; Humans; Japan; Liver; Male; Pilot Projects; Predictive Value of Tests; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness | 2019 |
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Water-Electrolyte Balance; Weight Loss | 2014 |
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Topics: Analysis of Variance; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome; Weight Loss | 2015 |
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Topics: Analysis of Variance; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Risk Factors; Treatment Outcome; Urinary Tract Infections | 2015 |
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
Topics: Aged; Arteriosclerosis; Benzhydryl Compounds; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Glucosides; Heart Rate; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Risk; Vascular Resistance; Vascular Stiffness | 2015 |
[Diabetes mellitus. SGLT2 inhibitor reduces cardiovascular mortality].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Combined Modality Therapy; Diabetic Angiopathies; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate | 2015 |
[SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis | 2015 |
Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
Topics: Adult; Aged; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Prospective Studies; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2016 |
29 other study(ies) available for glucose, (beta-d)-isomer and Diabetic Angiopathies
| Article | Year |
|---|---|
Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK/NF-κB/NLRP3 signaling pathway in AGEs-induced HUVECs.
Topics: AMP-Activated Protein Kinases; Cell Line; Diabetic Angiopathies; Endothelium, Vascular; Glucosides; Glycation End Products, Advanced; Human Umbilical Vein Endothelial Cells; Humans; Inflammasomes; Inflammation; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Phenols; Reactive Oxygen Species; RNA-Seq; Signal Transduction; Transcription Factor RelA | 2020 |
Topics: Adult; Benzhydryl Compounds; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug-Related Side Effects and Adverse Reactions; Female; Glucosides; Heart Failure; Humans; Male; Mortality; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2020 |
Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Observational Studies as Topic; Practice Patterns, Physicians'; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Male; Prognosis; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Linagliptin; Male; Membrane Transport Modulators; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?
Topics: Albuminuria; Anti-Inflammatory Agents; Benzhydryl Compounds; Cardiovascular Diseases; Cytokines; Diabetes Complications; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Heart; Humans; Hypertension, Renal; Hypoglycemic Agents; Kidney; Oxidative Stress; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2017 |
EMPA-REG OUTCOME: The Nephrologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
EMPA-REG OUTCOME: The Cardiologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2017 |
EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
EMPA-REG OUTCOME: The Nephrologist's Point of View.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Incidence; Kaplan-Meier Estimate; Male; Membrane Transport Modulators; Middle Aged; Norway; Proportional Hazards Models; Risk; Sodium-Glucose Transporter 2; Sweden | 2018 |
Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Costs; Female; Glucosides; Humans; Male; Middle Aged; Morbidity; Quality-Adjusted Life Years; Risk Factors; Treatment Outcome | 2018 |
What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?
Topics: Benzhydryl Compounds; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors | 2018 |
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Gastrointestinal Microbiome; Glucosides; Intestines; Male; Mice; Muscle, Smooth, Vascular; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Stiffness; Vasodilation | 2018 |
Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
Topics: Adult; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Incidence; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Endothelium, Vascular; Female; Glucosides; Glycosuria; GPI-Linked Proteins; Humans; Kidney; Mice, Inbred C57BL; Mice, Mutant Strains; Pulsatile Flow; Renal Circulation; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Resistance; Vascular Stiffness; Vasodilation | 2018 |
Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Carbon-13 Magnetic Resonance Spectroscopy; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Glucose; Glucosides; Heart; Ketones; Male; Myocardium; Obesity; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Weight Gain | 2019 |
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
Topics: Aged; Albumins; Albuminuria; Benzhydryl Compounds; Biomarkers; Clinical Trials, Phase III as Topic; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Down-Regulation; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors | 2019 |
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Humans; Male; Middle Aged; Research Design; Sweden; Treatment Outcome | 2019 |
Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2019 |
Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Humans; Male; Middle Aged; Models, Economic; Patient Simulation; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Supplementation of cyanidin-3-O-β-glucoside promotes endothelial repair and prevents enhanced atherogenesis in diabetic apolipoprotein E-deficient mice.
Topics: Acetylcholine; AMP-Activated Protein Kinases; Animals; Anthocyanins; Aorta; Apolipoproteins E; Atherosclerosis; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diet; Dietary Supplements; Endothelial Cells; Endothelium; Glucosides; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Stem Cells; Streptozocin; Wound Healing | 2013 |
Emodin-6-O-β-D--glucoside inhibits high-glucose-induced vascular inflammation.
Topics: Animals; Anti-Inflammatory Agents; Capillary Permeability; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Coculture Techniques; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Emodin; Endothelial Cells; Glucose; Glucosides; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred C57BL; Monocytes; NF-kappa B; Oxidative Stress; Reactive Oxygen Species; Vasculitis | 2014 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Kidney Failure, Chronic; Metformin; Microcirculation; Middle Aged; Myocardial Infarction; Nutrition Surveys; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Uric Acid | 2014 |
The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cytokines; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Gene Expression; Glucose; Glucosides; Hemodynamics; Inflammation Mediators; Insulin; Male; Oxidative Stress; Rats; Receptor for Advanced Glycation End Products; Receptors, Immunologic; RNA, Messenger; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin | 2014 |
Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart; Humans; Hypoglycemic Agents; Models, Biological; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Models, Biological; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Approval; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Mortality; Multicenter Studies as Topic; Survival Analysis | 2017 |